Cognition Platform Study in Participants at Risk for Alzheimer's Disease (AD) (MK-0000-413)

Mild Cognitive Impairment Clinical Trial

Official title:

A Clinical Study to Evaluate a Cognitive Platform to Support Development of Symptomatic Therapies in Participants at Risk for Alzheimer's Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04730635
• Other study ID #: 0000-413
• Secondary ID: MK-0000-413
• Status: Completed
• Phase: Phase 1
• Start date: March 23, 2021
• Est. completion date: February 6, 2023

Study information

• Verified date: February 2023
• Source: Merck Sharp & Dohme LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main purpose of this study is to assess the ability of a repeated high-frequency site-based computerized cognitive assessment to evaluate the potential treatment effects of donepezil (MK-0000) compared with placebo among participants with mild cognitive impairment (MCI) or mild Alzheimer's Disease (AD). The primary study hypothesis is that the average percentage of correct responses on one card learning (OCL) task will be ≥2 percentage points in participants receiving donepezil compared with participants receiving placebo.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 44
• Est. completion date: February 6, 2023
• Est. primary completion date: January 20, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 55 Years to 85 Years

Eligibility

Inclusion Criteria:

• Has an Mini Mental State Examination (MMSE) score between 18 and 28 (inclusive) at Screening (Visit 1) and Baseline (Visit 2)

• Has a diagnosis of mild cognitive impairment (MCI) or mild Alzheimer's Disease (AD)

• Has an Modified Hachinski Ischemia Scale (MHIS) score of =4

• Must have a reliable and competent study partner/informant who accompanies participant to study visits and participates in assessments

• Be willing to provide a blood sample for Apolipoprotein E (APOE) genotyping

• Does not have intellectual disability

• Be able to speak, read, hear, and understand the language of the study staff and the Informed Consent Form (ICF)

• Be able and willing to adhere to the study visit schedule

• Have visual acuity, visual function, hearing, and gross and fine motor skills adequate to support study participation

• Be capable of performing the Cogstate battery assessments, as demonstrated at the Baseline/Familiarization Visit (Visit 2)

• A female participant is eligible to participate if she is a woman of nonchildbearing potential (WONCBP)

Exclusion Criteria:

• Is at imminent risk of self-harm

• Has evidence of a clinically relevant neurological disorder other than AD at screening, including but not limited to: Parkinson's disease, frontotemporal dementia, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, progressive supranuclear palsy, dementia with Lewy bodies, other types of dementia, neurosyphilis or that led to persistent cognitive deficits, or has a history of seizures or epilepsy within the last 5 years before screening

• Has a known history of stroke or has a diagnosis of vascular dementia

• Has history of multiple episodes of head trauma, or head trauma resulting in protracted loss of consciousness, or serious infectious disease affecting the brain, within the prior 3-5 years

• Has evidence of a clinically relevant or unstable psychiatric disorder, based on Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5), including schizophrenia or other psychotic disorder, bipolar disorder, major depression, or delirium

• Has a recent or ongoing, uncontrolled, clinically significant medical condition within 2 months of the Screening visit

• Has a history of cancer

• Has a relative contraindication to donepezil including sick sinus syndrome, first, second, or third-degree heart block, bradycardia, active gastrointestinal (GI) bleeding, Zollinger-Ellison syndrome, uncontrolled peptic ulcer disease, or uncontrolled asthma

• Has a history of significant multiple and/or severe allergies or has had an anaphylactic reaction or significant intolerability to prescription or non-prescription drugs or food. Exception: Participants with selected allergies may be enrolled with Sponsor's approval

• Is positive for Hepatitis B surface antigen (HBsAg), hepatitis C antibodies or human immunodeficiency virus (HIV) [participants with a history of chronic hepatitis C virus with a documented cure and/or a positive serologic test for HCV with a negative HCV viral load may be included]

• Has clinically significant vitamin B12 or folate deficiency in the 6 months immediately before screening, or vitamin B12 or folate deficiency in addition to increased serum homocysteine and methylmalonic acid levels at screening

• Has prior AD treatment

• Has participated in another investigational study within 4 weeks

• Has a known history of structural changes on screening magnetic resonance imaging (MRI) scan that are clinically important, including signs indicative of vascular dementia, large infarct, lacunes in critical areas, space-occupying lesions, or extensive white matter disease

• Is unwilling to or not eligible to undergo a MRI scan (if a prior MRI scan is not available)

• Is pregnant, is attempting to become pregnant, or is nursing children

• Has a history of alcoholism or drug dependency/abuse within the last 5 years prior to the Screening visit

• Consumes greater than 3 glasses of alcoholic beverages per day

• Consumes excessive amounts, defined as greater than 6 servings of coffee, tea, cola, energy drinks, or other caffeinated beverages per day

• Is a regular user of cannabis, any illicit drugs or has a history of drug abuse within approximately 5 years. A participant who is a recreational user of cannabis or other drugs within the past 2 years can be enrolled as long as recreational use does not meet the definition of drug abuse and participant agrees to refrain from substance use for duration of study participation

• Participants must have a negative urine drug screen (UDS) prior to randomization

• Had major surgery within 3 months prior to the Screening visit that would interfere in the participant's ability to fully participate in the study

• Has undergone neuropsychological testing (including the MMSE) or cognitive remediation in the past 4 weeks

• Is or has an immediate family member who is investigational site or Sponsor staff directly involved with this study

Related Conditions & MeSH terms

• Alzheimer Disease
• Alzheimer's Disease
• Cognitive Dysfunction
• Mild Cognitive Impairment

Intervention

Drug:
• Donepezil
Donepezil 5 mg capsules for a total daily dose of up to 10 mg QD, orally, for Days 1-56.
• Placebo
Dose matched placebo capsule QD, orally for Days 1-56.

Locations

Country	Name	City	State
Australia	Royal Adelaide Hospital-CALHN Memory Trials ( Site 0031)	Adelaide	South Australia
Australia	Austin Health ( Site 0030)	Heidelberg	Victoria
United States	Pennington Biomedical Research Center ( Site 0006)	Baton Rouge	Louisiana
United States	Insight Clinical Trials ( Site 0020)	Beachwood	Ohio
United States	iResearch Atlanta ( Site 0005)	Decatur	Georgia
United States	North Texas Clinical Trials - Fort Worth - West Rosedale ( Site 0022)	Fort Worth	Texas
United States	Velocity Clinical Research, Hallandale Beach ( Site 0013)	Hallandale Beach	Florida
United States	Charter Research - Lady Lake ( Site 0025)	Lady Lake	Florida
United States	Collaborative Neuroscience Network ( Site 0010)	Long Beach	California
United States	iResearch Savannah ( Site 0023)	Savannah	Georgia

Sponsors (1)

Lead Sponsor	Collaborator
Merck Sharp & Dohme LLC

Countries where clinical trial is conducted

United States,  Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage Change From Baseline in Correct Responses on the One Card Learning (OCL) Task to Week 8	OCL uses a pattern separation paradigm to assess visual memory. Tthe percentage change from baseline in correct responses on the OCL task up to Week 8 will be compared in participants receiving donepezil with participants receiving placebo.	Baseline, Up to Week 8
Secondary	Percentage Change From Baseline in the Overall Standard Deviation (sd) in Average OCL Task (Arcsine Square Root Transformed) to Week 8	OCL uses a pattern separation paradigm to assess visual memory. The percentage change from baseline in correct responses on the OCL task up to Week 8 will be compared in participants receiving donepezil with participants receiving placebo.	Baseline, Up to Week 8
Secondary	Percentage of Correct Responses on the OCL Task	OCL uses a pattern separation paradigm to assess visual memory. The percentage of correct responses on the OCL task will be compared in participants receiving donepezil with participants receiving placebo up to approximately Week 8.	Up to approximately Week 8